These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Search MEDLINE/PubMed


  • Title: [Effects comparison of lamivudine therapy for hepatitis B virus genotypes B and C].
    Author: Zhou JL, Wu SP.
    Journal: Zhonghua Gan Zang Bing Za Zhi; 2004 Aug; 12(8):489-90. PubMed ID: 15329211.
    Abstract:
    OBJECTIVE: To determine the lamivudine response of HBV genotypes in patients with HBV DNA positive chronic hepatitis. METHODS: Clinical data from 235 patients in the original trial were analyzed. RESULTS: 135 patients received lamivudine and 100 patients as controls. Almost all patients had HBV genotypes B or C. Antiviral response were 92.9% and 75.9% in lamivudine-treated patients (chi-square = 6.628, P < 0.05) and 9.8% and 8.5% in untreated controls (P > 0.05) with HBV genotype B and C, respectively. The incidences of lamivudine-induced mutation in YMDD motif were 3.6% and 16.5% in HBV genotype B and C, respectively (chi-square = 5.508, P < 0.01). We identified HBV genotype B, elevated pretreatment alanine aminotransferase (ALT) levels, and low pretreatment HBV DNA levels as independent factors associated with antiviral response. CONCLUSION: HBV genotype B was associated with a higher rate of lamivudine-induced HBV DNA clearance and lower rate of lamivudine-induced YMDD mutation compared with genotype C. HBV genotypes may be an important determinant of lamivudine therapy of chronic hepatitis B.
    [Abstract] [Full Text] [Related] [New Search]